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Abstract: The -2 and -3 adrenergic receptors (ADRB2 and ADRB3) are thought to play a role in energy expenditure and lipolysis.
However, the effects of the ADRB2 glutamine (Gln) 27 glutamic acid (glutamate) (Glu) and ADRB3 tryptophan (Trp) 64 arginine
(Arg) polymorphisms on weight loss remain controversial. The aim of this study was to investigate the effect of these polymor-
phisms on changes in weight and body composition during a controlled weight-loss program. One hundred seventy-three
healthy overweight and obese participants (91 women, 82 men) aged 18–50 years participated in a 22-week-long intervention
based on a hypocaloric diet and exercise. They were randomly assigned to 1 of 4 groups: strength, endurance, strength and
endurance combined, and physical activity recommendations only. Body weight, body mass index (BMI), and body composition
variables were assessed before and after the intervention. Genetic analysis was carried out according to standard protocols. No
effect of the ADRB2 gene was shown on ﬁnal weight, BMI, or body composition, although in the supervised male group, Glu27
carriers tended to have greater weight (p = 0.019, 2.5 kg) and BMI (p = 0.019, 0.88 kg/m2) reductions than did noncarriers. There
seems to be an individual effect of the ADRB3 polymorphism on fat mass (p = 0.004) and fat percentage (p = 0.036), in addition to
an interaction with exercise for fat mass (p = 0.038). After the intervention, carriers of the Arg64 allele had a greater fat mass and
fat percentage than did noncarriers (p = 0.004, 2.8 kg). In conclusion, the ADRB2 Gln27Glu and ADRB3 Trp64Arg polymorphisms
may inﬂuence weight loss and body composition, although the current evidence is weak; however, further studies are necessary
to clarify their roles.
Key words: -adrenergic receptors, weight loss, body composition, Gln27Glu and Trp64Arg, exercise and diet.
Résumé : Les récepteurs -2 et -3 adrénergiques (ADRB2, ADRB3) jouent un rôle, selon des études, dans la dépense d’énergie et
la lipolyse. Toutefois, les effets des polymorphismes ADRB2 Gln27Glu et ADRB3 Trp64Arg sur la perte de poids soulèvent la
controverse. Cette étude a pour objectif d’examiner l’effet de ces polymorphismes sur la modiﬁcation de la masse et de la
composition corporelles au cours d’un programme de perte de poids sous supervision. Cent soixante-treize sujets en surpoids et
obèses (91 femmes, 82 hommes) âgés de 18 a` 50 ans participent a` un programme supervisé d’une durée de 22 semaines et
comprenant un régime hypocalorique et de l’exercice physique. On répartit aléatoirement les sujets dans 4 groupes : force,
endurance, force et endurance, recommandations enmatière d’activité physique. Avant et après les 22 semaines d’intervention,
on évalue lamasse corporelle, l’indice demasse corporelle (IMC) et la composition corporelle. On effectue une analyse génétique
au moyen des protocoles usuels. On n’observe aucun effet du gène ADRB2 sur la masse corporelle, l’IMC et la composition
corporelle en ﬁn d’intervention; toutefois, les porteurs de Glu27 dans le groupe masculin supervisé présentent une tendance a`
une perte de poids plus grande (p = 0,019, 2,5 kg) et a` un abaissement de l’IMC (p = 0,019, 0,88 kg/m2) comparativement aux sujets
non porteurs. On observe possiblement un effet individuel du polymorphisme ADRB3 sur la masse adipeuse (p = 0,004) et le
pourcentage de gras (p = 0,036), indépendamment de l’interaction de la masse adipeuse avec l’exercice physique (p = 0,038). Les
porteurs de l’allèle Arg64 présentent des valeurs plus élevées de masse adipeuse et de pourcentage de gras que les non-porteurs
a` la ﬁn de l’intervention (p = 0,004, 2,8 kg). In conclusion, les polymorphismes ADRB2 Gln27Glu et ADRB3 Trp64Arg pourraient
avoir un effet sur la perte de poids et la composition corporelle, mais les données de cette étude sont peu probantes; il faut donc
effectuer d’autres études pour élucider leurs rôles. [Traduit par la Rédaction]
Mots-clés : récepteurs -adrénergiques, perte de poids, composition corporelle, Gln27Glu, Trp64Arg, exercice physique, diète.
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Introduction
The response to weight-loss programs is inﬂuenced by genetic
factors (Bouchard 2008; Loos and Rankinen 2005; Ordovas and Shen
2008); therefore, it is essential to understand the genetic and bio-
logical background of obesity and the weight-loss processes to
prevent and treat this complex disease. Energy balance is regulated
by the adrenergic system (Blaak et al. 1993; Monroe et al. 2001);
both the -2 and the -3 adrenergic receptor (ADRB2 and ADRB3)
promote lipolysis and fatmobilization andmodify glucosemetab-
olism (Arner 1992; Enoksson et al. 2000; Hagstrom-Toft et al. 1998;
Lafontan et al. 1997). The lipolysis function is even more impor-
tant during exercise and energy restriction (Arner 1992, 1995).
Common polymorphisms, the glutamine (Gln) 27 glutamic acid
(glutamate) (Glu) of the ADRB2 gene and the tryptophan (Trp) 64
arginine (Arg) of the ADRB3 gene, imply structural and functional
differences among the protein versions and thus can inﬂuence
body weight (Gagnon et al. 1996; Garenc et al. 2003; Green et al.
1995). In epidemiological studies of the ADRB2 gene, some re-
searchers found no relationship between the Gln27Glu polymor-
phism and obesity-related phenotypes (Bea et al. 2010; Echwald
et al. 1998; Kortner et al. 1999; Rosado et al. 2015). However, other
researchers found that the Glu27 is the risk allele for obesity
(Clement et al. 1995; Gonzalez Sanchez et al. 2003; Lange et al.
2005; Large et al. 1997), and still others, on the contrary, reported
that the Glu27 is the favorable allele, protective against obesity
(Meirhaeghe et al. 2000; Pereira et al. 2003). As for the ADRB3 gene,
although in some cases no association was shown between the
Trp64Arg polymorphism and obesity (Bea et al. 2010; Gagnon et al.
1996), other studies showed that the Trp64 allele is protective
against obesity (Clement et al. 1995; Corella et al. 2001; Ukkola
et al. 2000; Widen et al. 1995).
An interaction among the gene, physical activity, and obesity
has been suggested for both polymorphisms. Arner (2000) found
different effects of the Glu27 allele in sedentary and active people,
and differences in fat oxidation were reported between Glu27 and
Gln27 allele carriers in 2 studies (Macho-Azcarate et al. 2002;
Rosado et al. 2015). Meirhaeghe and colleagues (1999) suggested
that physical activity can counteract the effect of the Gln27Glu
polymorphism in weight control, whereas for the ADRB3 gene,
Marti and colleagues (2002) observed a different risk of obesity
with the Trp64Arg polymorphism.
As far as we know, no interventional studies have included both
controlled exercise and a diet program and the polymorphisms
that we have analyzed. In the case of the ADRB2 gene, no signiﬁ-
cant main effect of the Gln27Glu polymorphism on changes in
body weight or body composition after a program based on resis-
tance training was found in women (Bea et al. 2010); similarly,
Rauhio and colleagues (2013) found no main effect with a diet inter-
vention including weight maintenance. However, in the HERITAGE
study, Glu27 carriers lost more body fat mass (Garenc et al. 2003).
Applying only a diet intervention, Ruiz et and colleagues (2011) re-
ported that the female Glu27 allele carriers had greater reductions
in body weight, body mass index (BMI), and lean mass. For the
ADRB3 gene, previous studies showed nomain individual effect of
this polymorphism (Bea et al. 2010; Ukkola et al. 2003); however,
Bea and colleagues (2010) reported that in nonexercisers, the car-
riers of the Arg64 allele gained a greater percentage of body fat. No
differences between Arg64 allele carriers and noncarriers were
found in bodyweight and body fat in response to weight loss, but
the loss of visceral adipose tissue (VAT) was 43% lower in the
Arg64 allele carriers (Tchernof et al. 2000). On the contrary, Phares
and colleagues (2004) concluded that the Arg64 allele carriers had
a 2 times greater loss of percentage body fat.
In contrast to the candidate gene studies, no genome-wide as-
sociation studies (GWASs) have shown an association between
these polymorphisms and BMI, adiposity, or fat distribution (Fox
et al. 2012; Locke et al. 2015; Shungin et al. 2015; Speliotes et al.
2010), which casts doubt on the previous ﬁndings. To the best of
our knowledge, there has been no GWAS carried out on body
composition changes during a weight-loss program. Despite these
controversies, both polymorphisms are of interest regarding obe-
sity and weight loss. Consequently, the aim of the current study
was to analyze the effect of 2 common polymorphisms, ADRB2
Gln27Glu and ADRB3 Trp64Arg, on changes in body weight, BMI,
and fat distribution during a highly controlled exercise and diet
weight-loss programand to examine the inﬂuence of these polymor-
phisms on baseline values for the aforementioned parameters.
Materials and methods
This study is part of the randomized controlled trial (RCT) Nu-
trition and Physical Activity Programs for Obesity Treatments (the
PRONAF study according to its Spanish initials) (ClinicalTrials.gov
ID: NCT01116856). The RCT, whose aim was to assess the useful-
ness of different types of physical activity and nutrition programs
in the treatment of adult obesity, was conducted in 2010 and 2011
following the ethical guidelines of the Declaration of Helsinki.
The Human Research Review Committee of the University Hospi-
tal La Paz reviewed and approved the study design and the re-
search protocol (code of approval PI-643). Further details of the
study are described elsewhere (Zapico et al. 2012).
Subjects
The study participants were recruited through advertisements
covering a wide variety of media (television, radio, press, and
Internet). A total of 2319 potential participants were informed
about the nature of the study, and those who were 18 to 50 years
old, had a BMI between 25 and 34.9 kg/m2, were nonsmokers,
were sedentary (i.e., 2 h or less of structured exercise per week)
(Brochuet al. 2009), andhadglucosevalues<5.6mmol/L (<100mg/dL)
(Rutter et al. 2012) were invited to participate in the study.Women
with any disturbances inmenstrual cycle were not eligible. A ﬂow
diagram of the participants and details on dropouts can be found
elsewhere (Zapico et al. 2012). Participants provided written in-
formed consent prior to joining the study and completed a base-
line assessment at the medical center, after which they were
randomly assigned to groups.
Study design
The intervention was a 6-month diet and exercise-based pro-
gram focusing on a behavior change. Participants entered into the
study in 2 phases, in the ﬁrst year overweight, in the second year
obese subjects, andwere split into 4 randomly assignedgroups, strat-
iﬁed by age and sex: strength (S), endurance (E), combined strength
and endurance (SE), and the control group with physical activity
recommendations only (C). For all participants, the measurements
took place before starting, in week 1, and after 22 weeks of interven-
tion, in week 24. Physical activity was assessed by a SenseWear Pro3
Armband accelerometer (Body Media, Pittsburgh, Pa., USA). Partici-
pants wore the monitor continuously for 5 days, including
weekends and weekdays, following general recommendations
(Murphy 2009). Daily energy expenditure was calculated using
the Body Media propriety algorithm (Interview Research Soft-
ware, version 6.0; BodyMedia Inc., Pittsburgh,. Pa., USA). Addition-
ally, participants were asked to report physical activity habits and
the amount of any food consumed during the intervention
through a personal diary.
Diet intervention
Before the intervention, negative energy balancewas calculated
for all participants, taking into account their own daily energy
expenditure, based on accelerometry data and the 3-day food
record; they followed an individualized hypocaloric diet with a
25%–30% caloric restriction (National Institutes of Health 1998).
Macronutrient distribution was set according to Spanish Society
of Community Nutrition recommendations (Dapcich et al. 2004).
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Exercise intervention
All exercise training groups (S, E, and SE) followed an indi-
vidualized training program, which consisted of exercise ses-
sions 3 times per week for 22 weeks, carefully supervised by
certiﬁed personal trainers. Details of the different protocols de-
veloped by the groups are described elsewhere (Zapico et al. 2012).
Control group
Participants in the C group followed the dietary intervention
and the physical activity recommendations of the American Col-
lege of Sports Medicine (Donnelly et al. 2009) and thus were ad-
vised to undertake at least 200–300 min of moderate-intensity
physical activity per week.
Adherence to diet was calculated as the estimated kilocalories
of the diet divided by the real kilocalorie intake in percentage ((esti-
mated kcal of diet/real kcal intake) × 100), 100% being the greatest
adherence, following a methodology used previously (Acharya et al.
2009). Moreover, adherence to exercise was calculated by the num-
ber of sessions completed in regard to the theoretical sessions ((ses-
sions performed/total sessions) × 100). Participants achieving 90%
adherence to exercise (Hunter et al. 2000) and 80% to diet (Del Corral
et al. 2009) were included in the analysis.
Body composition
Anthropometric measures included height measured to 0.01 m
(SECA stadiometer, Seca Ltd., Valencia, Spain) and body weightmea-
sured to 0.1 kg (TANITA BC-420MA balance, Bio Lógica Tecnología
Médica S.L, Barcelona, Spain). BMI was calculated as body weight
(kg)/(height (m2). Body composition (fatmass (kg), abdominal fat (kg),
VAT (kg)) was assessed by dual-energy X-ray absorptiometry (GE
Lunar Prodigy, GE Healthcare, Madison, Wis., USA) and GE Encore
2002 (version 6.10.029) software (GE Healthcare) with an accuracy of
0.001 kg. Percentage body fat was calculated as (fat (kg)/body weight
(kg)) × 100%.
Genetic analysis
Whole blood samples (5 mL) from each participant were col-
lected in EDTA and were sent to the laboratory for analysis. DNA
was extracted from each sample using the QIAamp DNA Blood
MiniKit (QIAGEN,Hilden,Germany), andgenotypingwasperformed
for each single nucleotide polymorphism (SNP). For the overweight
participants, analysis of the ADRB2 Gln27Glu (rs1042714) and the
ADRB3 Trp64Arg (rs4994) polymorphisms was done using PCR and
restriction fragment length polymorphism techniques described
previously (Clement et al. 1995; Large et al. 1997). For the obese par-
ticipants, genotyping of the 2 polymorphisms was carried out using
the corresponding TaqMan SNP Genotyping Assays (Applied Biosys-
tems, Foster City, Calif., USA) with the StepOne Real Time PCR Sys-
tem (Applied Biosystems).
Statistical analyses
The statistical analysis was performed using IBM SPSS Statistics
for Windows, version 22.0 (IBM Corp., Armonk, N.Y., USA). A 2
test was used to assess whether observed genotype frequencies
were in the Hardy–Weinberg equilibrium. Normal distribution of
each dependent variable was tested using quantile-quantile plots,
and when needed, a Box–Cox transformation was applied using
the optimal  value. Three genetic models (additive, dominant,
and recessive) were tested for the ADRB2 gene; however, for the
ADRB3, 2 groups (carriers and noncarriers of the Arg64 allele) were
analyzed because of the low number of homozygotes for the
Arg64 allele. Based on exercise, the sample was divided into
2 groups: supervised (S, E, SE groups) with all protocols having the
same characteristics (intensity, duration, and frequency) and non-
supervised (C group). Three-way (genotype × exercise type × sex)
analysis of covariance (ANCOVA) was conducted, using the ﬁnal
values of weight and body composition parameters adjusted by
age and initial values to reveal differences between genotype
groups, men and women, and exercise groups, as well possible
interactions. Two-way (genotype × sex) ANCOVA was performed,
adjusted by age for BMI and percentage body fat at baseline to
determine the initial differences between genotype groups and
sexes. Statistical signiﬁcance for postintervention comparisons
was deﬁned at the corrected  of 0.00179 for the ADRB2 and
0.00625 for the ADRB3 polymorphism, for baseline comparisons at
0.00357 for the ADRB2 and 0.0125 for the ADRB3 polymorphism,
with correction for repeated tests across the levels of the ANCOVA
model factors, where appropriate.
Results
The baseline characteristics of the 173 subjects who partici-
pated in the study (after dropouts, exclusions because of low ad-
herence, and missing data) are shown in Table 1.
Genotype distributions and allele frequencies of the ADRB2
Gln27Glu and ADRB3 Trp64Arg polymorphisms are shown in Tables 2
and 3. Both genotype distributions were found to be in Hardy–
Weinberg equilibrium (p = 0.987 for the ADRB2 and p = 0.980 for
the ADRB3 polymorphism).
ADRB2 Gln27Glu postintervention comparisons
Results for the dominant model are shown; no signiﬁcant results
were found with the other models. Based on these data, it appears
that thismodel is the one that best ﬁts the behavior of this polymor-
phism. We observed no main effect of the Gln27Glu polymorphism
for ﬁnal body composition values, which were adjusted by initial
measurements, or for interaction with exercise, sex, or both. Post
hoc analyses revealed thatwithin the supervisedmengroup, carriers
of theGlu27allele reducedweight andBMImore thandidnoncarriers
(p = 0.019, 2.52 kg, and p = 0.019, 0.881 kg/m2 respectively) (Fig. 1). No
differences were found for the other variables. (Figs. 1 and 2).
Table 1. Baseline characteristics of the subjects.
ADRB2 ADRB3
Glu27
noncarrier
Glu27
carrier
Arg64
noncarrier
Arg64
carrier
Baseline women
n 37 54 76 15
Age (y) 38.24±8.45 39.72±8.16 39.61±7.93 36.67±9.75
Body weight (kg) 79.16±9.86 81.82±10.96 81.08±10.58 79.03±10.57
BMI (kg/m2) 29.81±2.67 30.93±3.48 30.64±3.08 29.67±3.78
Fat mass (kg) 34.17±5.19 35.63±7.1 35.3±6.37 33.78±6.73
Fat percentage (%) 44.93±3.53 45.29±4.37 45.3±3.99 44.41±4.35
Android fat (kg) 2.82±0.57 2.94±0.81 2.92±0.72 2.74±0.72
VAT (kg) 0.71±0.34 0.79±0.38 0.77±0.35 0.69±0.44
Baseline men
n 28 54 73 9
Age (y) 39.39±7.15 39.78±8.82 39.88±8.09 37.78±9.74
Body weight (kg) 97.02±11.47 95.45±10.39 95.86±10.24 97.03±14.84
BMI (kg/m2) 31.27±2.46 30.78±2.85 30.91±2.6 31.25±3.67
Fat mass (kg) 33.28±7.59 33.75±6.72 33.63±6.84 33.23±8.5
Fat percentage (%) 35.48±4.78 36.82±4.75 36.49±4.73 35.29±5.32
Android fat (kg) 3.43±0.96 3.44±0.93 3.46±0.88 3.24±1.31
VAT (kg) 1.76±0.69 1.74±0.73 1.79±0.68 1.38±0.94
Note:Data presented as means ± SD. ADRB2, -2 adrenergic receptor; ADRB3,
-3 adrenergic receptor; Glu, glutamic acid (glutamate); Arg, arginine; BMI, body
mass index; VAT, visceral adipose tissue.
Table 2. Genotype distribution and allele frequency of the ADRB2 gene.
Gln27Gln Gln27Glu Glu27Glu Allele Gln27 Allele Glu27
All 65 (37.57) 82 (47.40) 26 (15.03) 212 (0.61) 134 (0.39)
Women 37 (40.65) 40 (43.95) 14 (15.4) 114 (0.63) 68 (0.37)
Men 28 (34.14) 42 (51.22) 12 (14.64) 98 (0.60) 66 (0.40)
Note: Data presented as n (%) for genotypes and n (frequency) for alleles.
ADRB2, -2 adrenergic receptor; Gln, glutamine; Glu, glutamic acid (glutamate).
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ADRB3 Trp64Arg postintervention comparisons
Regarding the Trp64arg polymorphism, no differences were seen
for weight, BMI, android fat, or VAT (Figs. 3 and 4). An individual
effect of the polymorphism was found for fat mass (p = 0.004, F =
8.519 (1)) and percentage fat (p = 0.036, F = 4.457 (1)), for fat mass
reaching the corrected signiﬁcance level. Moreover, an interac-
tion with exercise was observed for fat mass (p = 0.038, F = 4.383
(1)). Post hoc analyses indicated that Arg64 carriers had greater fat
mass and fat percentages than did noncarriers after the interven-
tion (p = 0.004, 2.82 kg and p = 0.036, 1.83%, respectively). More-
over, the ﬁnal fat mass of the female Arg64 carriers was 3.9 kg
higher than that of the noncarriers (p = 0.004); more speciﬁc dif-
ferences were observed depending on the genotype and type of
exercise. The pairwise comparison showed that the women carry-
ing the Arg64 allele in the nonsupervised exercise group had a
greater ﬁnal fat mass (p = 0.004, 7.22 kg) (Fig. 4). Accordingly,
among the Arg64 carriers in the whole sample and in women, the
supervised group reduced fat mass more than did the nonsuper-
vised group (p = 0.019, 4.31 kg and p = 0.010, 6.59 kg, respectively).
Baseline
Neither of the analyzed polymorphisms, the Gln27Glu of the
ADRB2 gene or the Trp64Arg of the ADRB3 gene, showed a main
effect or interactionwith sex or age for BMI or percentage body fat
at baseline.
Discussion
In this work, we studied the role that 2 polymorphisms of the
-adrenergic receptors play in body composition changes after a
24-week-long diet and exercise intervention (supervised or non-
supervised exercise) in healthy, overweight, and obese subjects.
Our results suggest no strong inﬂuence of the ADRB2 Gln27Glu
Table 3. Genotype distribution and allele frequency of the ADRB3 gene.
Trp64Trp Trp64Arg Arg64Arg Allele Trp64 Allele Arg64
All 148 (85.55) 24 (13.87) 1 (0.58) 320 (0.92) 26 (0.08)
Women 76 (83.52) 15 (16.48) 0 (0) 167 (0.92) 15 (0.08)
Men 72 (87.80) 9 (10.98) 1 (1.22) 153 (0.93) 11 (0.07)
Note: Data presented as n (%) for genotypes and n (frequency) for alleles.
ADRB3, -3 adrenergic receptors; Trp, tryptophan; Arg, arginine.
Fig. 1. -2 adrenergic receptor glutamine (Gln) 27 glutamic acid
(glutamate) (Glu) polymorphism and weight and body composition
variables after the intervention in men and women. Means of ﬁnal
values of (a) weight, (b) body mass index (BMI), and (c) percentage body
fat (Fat%) are presented after adjustment for baseline values and age,
with 95% conﬁdence intervals. *, p < 0.05.
Fig. 2. -2 adrenergic receptor glutamine (Gln) 27 glutamic acid
(glutamate) (Glu) polymorphism and body composition variables
after the intervention in men and women. Means of ﬁnal values of
(a) fat mass, (b) android fat, and (c) visceral adipose tissue (VAT) are
presented after adjustment for baseline values and age, with
95% conﬁdence intervals.
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(rs1042714) or the ADRB3 Trp64Arg (rs4994) polymorphisms on
these variables, but some associations were found, which encour-
ages further studies.
The genotype distribution and allele frequencies of both polymor-
phisms in our sample were similar to those of the Iberian European
population of the 1000 Genomes Project (Abecasis et al. 2012) and to
previous Spanish studies on the ADRB2 gene (Gonzalez Sanchez
et al. 2003; Martinez et al. 2003) and the ADRB3 gene (Corella et al.
2001).
As mentioned before, previous studies with Caucasians included
an exercise protocol or diet only but not both; therefore, they are
not fully comparable with our intervention. Even though it has
been proven that in a weight-loss program, diet results in a higher
loss than does exercise alone (Franz et al. 2007), the best protocols
include both for the greatest beneﬁt (Clark 2015; Curioni and
Lourenco 2005). Moreover, the interaction between genes and
physical activity has been suggested by previous authors in con-
nection with adrenergic receptor genes (Corbalan et al. 2002;
Meirhaeghe et al. 1999; Phares et al. 2004).
ADRB2 Gln27Glu postintervention comparisons
No main effect or interactions of the polymorphism with other
between-subject factors were shown in our analyses for body com-
position parameters, which is similar to the ﬁndings of other
studies based on weight-loss programs (Bea et al. 2010; Phares
et al. 2004; Rauhio et al. 2013). However, post hoc analyses revealed
that supervised men carrying the Glu27 allele lost more weight
and lowered BMI more (<0.05) than did the men in the Gln27Gln
group, suggesting that supervised exercise and the Glu27 allele
together inmencanbebeneﬁcial for losingmoreweight. Inprevious
studies, the potential effect of this polymorphism on the weight or
BMI of Caucasian men was negative. Phares and colleagues (2004)
used diet stabilization (but no caloric restriction) and aerobic train-
ing in subjects (aged 50–75 years) with a mean BMI of 27.8 kg/m2,
whereas the HERITAGE study investigated only aerobic training
with obese subjects, and PRONAF consisted of a hypocaloric diet
and exercise program. Although all 3 programs were between 20
and 24 weeks long, our intensity was a bit lower than that of the
other 2 programs (PRONAF, 50%–60% of the heart rate reserve;
Fig. 3. -3 adrenergic receptor tryptophan (Trp) 64 arginine (Arg)
polymorphism and weight and body composition variables after the
intervention in men and women. Means of ﬁnal values of (a) weight,
(b) body mass index (BMI), and (c) percentage body fat (Fat%) are
presented after adjustment for baseline values and age, with
95% conﬁdence intervals.
Fig. 4. -3 adrenergic receptor tryptophan (Trp) 64 arginine (Arg)
polymorphism and body composition variables after the
intervention in men and women. Means of ﬁnal values of (a) fat
mass, (b) android fat, and (c) visceral adipose tissue (VAT) are
presented after adjustment for baseline values and age, with
95% conﬁdence intervals. *, p < 0.00625.
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Garenc and colleagues (2003), 55%–75% of the maximal oxygen con-
sumption; Phares and colleagues (2004), 50%–70% of the maximal
oxygen consumption), and our sessionswere longer (PRONAF, 51.15–
60 min; Garenc and colleagues (2003), 30–50 min; Phares and col-
leagues (2004), 20–40 min). Garenc and colleagues (2003) reported
greater fat mass changes in obese Glu27 homozygote men, results
that were not conﬁrmed in our study. As for women, most studies
have not conﬁrmed the importance of this polymorphism with ex-
erciseonlyorwithdiet only (Beaet al. 2010;Rauhioet al. 2013;Rosado
et al. 2015), ﬁndings that are in line with our negative results. Never-
theless, Ruiz and colleagues (2011) reported that after a low-energy
mixed diet in a sample very similar to ours, Glu27 carriers lost more
weight and had a lower BMI. The added feature in our study com-
pared with this study is the exercise, which could balance the differ-
ences reported by them, because no differences were found for
weight or BMI. On the contrary, the HERITAGE study found that
Glu27Glu women reduced percentage fat by less than the other
2 groups in response to endurance training (Garenc et al. 2003). No
differences were found for android fat or VAT in our analyses, but to
the best of our knowledge, no antecedents to the contrary have been
reported in the literature (Bea et al. 2010; Rauhio et al. 2013; Ukkola
et al. 2003).
ADRB3 Trp64Arg postintervention comparisons
The individual effect of the Arg64 allele was observed for fat mass
and percentage fat that reached the 0.05 level; for fat mass this
was observed at even the corrected threshold. Moreover, an inter-
action with exercise was found for fat mass. However, the main
effect of the Trp64Arg polymorphism was observed in the change
in other body composition variables and in any interactions with
exercise or sex. Previous negative results disagree with our results
on fatmass and fat percentage, but support the negative results of
the other variables (Garenc et al. 2001; Phares et al. 2004; Rawson
et al. 2002; Ukkola et al. 2003). No differences in weight or BMI
were seen between carriers and noncarriers, which is in agree-
ment with other studies reporting different weight-loss inter-
ventions (hypocaloric diet, aerobic training, resistance training)
with sedentary obese participants (Bea et al. 2010; Rawson et al.
2002; Tchernof et al. 2000; Ukkola et al. 2003). Nevertheless, post
hoc analyses showed that carriers of the Arg64 allele lost less fat
mass and reduced percentage fat less than did noncarriers during
the intervention, contrary to previous studies using a wide variety
of protocols (Garenc et al. 2001; Phares et al. 2004; Rawson et al.
2002; Tchernof et al. 2000; Ukkola et al. 2003). Among the Arg64
carriers, the nonsupervised group had higher ﬁnal fatmass values
than did the supervised group, whichmay suggest that supervised
exercise is beneﬁcial for these genotypes. The interaction be-
tween this gene and physical activity has been raised before. Marti
and colleagues (2002) reported that this polymorphism means
higher obesity risk in sedentary people than in active people,
which is in line with the results of other studies (Phares et al.
2004). In women, the carriers of the Arg64 allele lost less fat mass
than did noncarriers, and nonsupervised subjects lost less fat
mass than did supervised subjects. Nonsupervised female Arg64
carriers had a smaller reduction in fat mass than did noncarriers,
but this should be judged cautiously because this group was very
small. However, it should be pointed out that this ﬁnding is in line
with the ﬁndings of Marti and colleagues (2002). Similarly, Bea and
colleagues (2010) reported that after a 12-month-long resistance train-
ing program in sedentary postmenopausal women (from normal
weight to obese), Arg64 carriers gained a signiﬁcantly greater per-
centage of fat than did noncarriers. As for android fat and VAT,
differences were seen between carriers and noncarriers of the
Arg64 allele. Conversely, Tchernof and colleagues (2000) reported
that through a 13-month-long diet program, Arg64 carriers lost
43% less VAT than did the Trp64Trp group. This intervention was
much longer and from a dietary point of view, stricter, than ours,
which could have been a determinant.
The physiological changes of the receptor function caused by
the gene variations, together with the diet and exercise program,
could lead to a divergent lipolysis rate and a divergent amount of
fat loss as a response to our program. However, it is hard to con-
ﬁrm the underlying mechanisms of these differences for fat with
our data because the project did not include a deep physiological
or molecular investigation. It is well established that adrenergic
receptors play a role in fat mobilization and lipolysis (Arner 1992;
Enoksson et al. 2000; Hagstrom-Toft et al. 1998; Lafontan et al. 1997),
and this inﬂuence can be greater with exercise or diet (Arner 1992,
1995). In addition, the interaction between these polymorphisms
and physical activity has been studied, but its existence is still not
clear (Arner 2000; Meirhaeghe et al. 1999; Rosado et al. 2015). Our
results and those of previous studies encourage further research.
Baseline Gln27Glu and Trp64Arg polymorphisms
Our analyses showed no effect of the polymorphisms on BMI or
percentage body fat or the interaction between the polymor-
phisms and age or sex at baseline. Several studies, in agreement
with our results, did not ﬁnd an association between theGln27Glu
polymorphism of the ADRB2 gene and obesity or related parame-
ters (Bea et al. 2010; Echwald et al. 1998; Kortner et al. 1999). Most
positive ﬁndings with the Gln27Glu polymorphism suggest that
the favorable allele is the Gln27 allele, and that the Glu27 allele
contributes to obesity risk (Clement et al. 1995; Gonzalez Sanchez
et al. 2003; Lange et al. 2005, 1997). On the contrary, other
researchers showed that the Gln27 allele enhances the risk of obe-
sity (Meirhaeghe et al. 2000; Pereira et al. 2003). As for the
Trp64Arg polymorphism of the ADRB3 gene, no association was
found in various studies in different populations (Bea et al. 2010;
Gagnon et al. 1996); nevertheless, a favorable feature of the Trp64
allele was demonstrated in the HERITAGE study and others
(Clement et al. 1995; Corella et al. 2001; Ukkola et al. 2000; Widen
et al. 1995).
As we have shown, study ﬁndings are not in agreement. This
can be explained partly by study protocol, age of the subjects, and
obesity status differences. Moreover, it was suggested previously
that most candidate gene studies are underpowered, mainly be-
cause of the sample size and the lack of adjustment for multiple
testing (Bray et al. 2009). Meta-analyses are in linewith our results,
reporting no association between obesity and the ADRB2Gln27Glu
(Allison et al. 1998; Jalba et al. 2008) or ADRB3 Trp64Arg (Kurokawa
et al. 2008) in Europeans, although they do conﬁrm the impor-
tance in other races including Asians, Paciﬁc Islanders, and Amer-
ican Indians. Studies using new techniques (GWAS) also conﬁrm
these ﬁndings (Fox et al. 2012; Locke et al. 2015; Shungin et al.
2015; Speliotes et al. 2010).
A limitation of our work is the sample size. The main objective
of our study was not to explore the genetic background of weight
loss; thus, this part of the study is underpowered. A correction for
multiple testing was applied, taking into account the polymor-
phisms, the genetic models, the exercise groups, and the sexes,
yet all results below 0.05 were reported and discussed. Another
limitation of our study is that for ethical reasons there was no real
control group; all groups followed the individualized diet and
exercise programs or received physical activity recommendations.
However, the strength of our study is that both exercise and diet
were included in the weight-loss program and were controlled by
experts in the ﬁeld.
The conclusions of our study are that during an exercise and
diet program in the Spanish overweight and obese population,
male carriers of the Glu27 allele of the ADRB2 Gln27Glu polymor-
phism may have an advantage in lowering weight and BMI, and
the carriers of the Arg64 allele of the ADRB3 Trp64Arg polymor-
phism (especially women) may have more difﬁculty in losing fat
mass and percentage fat than do noncarriers. However, for Arg64
allele carriers, supervised exercise can help individuals lose more
fat mass (thus compensating for the effect of the allele), which
312 Appl. Physiol. Nutr. Metab. Vol. 41, 2016
Published by NRC Research Press
A
pp
l. 
Ph
ys
io
l. 
N
ut
r. 
M
et
ab
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Ba
rb
ar
a 
Sz
en
dr
ei
 o
n 
02
/2
9/
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
gives promising practical use. Nevertheless, the evidence is weak;
thus, more research is needed in this ﬁeld, with larger sample sizes
and controlled protocols that take into account all possible interac-
tions among diet, exercise, genetic background, and other factors.
Finally, physical activity seems to inﬂuence the effect of these poly-
morphisms during weight loss, as was suggested previously.
Conﬂict of interest statement
No conﬂicts of interest or funding are declared.
Acknowledgements
We thank all the voluntary subjects for their participation in
the study. The PRONAF Study takes place with the ﬁnancial sup-
port of the Ministerio de Ciencia e Innovación, Convocatoria de
Ayudas I+D 2008, Proyectos de Investigación Fundamental No Ori-
entada, del VI Plan de Investigación Nacional 2008–2011, (Contrac:
DEP2008-06354-C04-01). RC is funded by a predoctoral grant from
the Universidad Politécnica de Madrid.
References
Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M.,
Handsaker, R.E., et al. 2012. An integrated map of genetic variation from
1,092 human genomes. Nature, 491(7422): 56–65. doi:10.1038/nature11632.
PMID:23128226.
Acharya, S.D., Elci, O.U., Sereika, S.M., Music, E., Styn, M.A., Turk, M.W., et al.
2009. Adherence to a behavioral weight loss treatment program enhances
weight loss and improvements in biomarkers. Patient Prefer. Adherence, 3:
151–160. PMID:19936157.
Allison, D., Heo, M., Faith, M., and Pietrobelli, A. 1998. Meta-analysis of the
association of the Trp64Arg polymorphism in the beta3 adrenergic receptor
with body mass index. Int. J. Obes. Relat. Metab. Disord. 22(6): 559–566.
doi:10.1038/sj.ijo.0800625. PMID:9665677.
Arner, P. 1992. Adrenergic receptor function in fat cells. Am. J. Clin. Nutr.
55(1 Suppl.): 228S–236S. PMID:1309480.
Arner, P. 1995. The beta 3-adrenergic receptor–a cause and cure of obesity?
N. Engl. J. Med. 333(6): 382–383. doi:10.1056/NEJM199508103330612. PMID:
7609759.
Arner, P. 2000. Obesity–a genetic disease of adipose tissue? Br. J. Nutr. 83(Suppl.
1): S9–S16. doi:10.1017/S0007114500000891. PMID:10889786.
Bea, J.W., Lohman, T.G., Cussler, E.C., Going, S.B., and Thompson, P.A. 2010.
Lifestyle modiﬁes the relationship between body composition and adrener-
gic receptor genetic polymorphisms, ADRB2, ADRB3 and ADRA2B: a second-
ary analysis of a randomized controlled trial of physical activity among
postmenopausal women. Behav. Genet. 40(5): 649–659. doi:10.1007/s10519-
010-9361-1. PMID:20401689.
Blaak, E.E., van Baak, M.A., Kempen, K.P., and Saris, W.H. 1993. Role of alpha-
and beta-adrenoceptors in sympathetically mediated thermogenesis. Am. J.
Physiol. 264(1): E11–E17. PMID:8094272.
Bouchard, C. 2008. Gene-environment interactions in the etiology of obesity:
deﬁning the fundamentals. Obesity, 16(S3): S5–S10. doi:10.1038/oby.2008.528.
PMID:19037213.
Bray, M.S., Hagberg, J.M., Perusse, L., Rankinen, T., Roth, S.M., Wolfarth, B., et al.
2009. The human gene map for performance and health-related ﬁtness phe-
notypes: the 2006–2007 update. Med. Sci. Sports Exerc. 41(1): 35–73. doi:10.
1249/MSS.0b013e3181844179. PMID:19123262.
Brochu, M., Malita, M.F., Messier, V., Doucet, E., Strychar, I., Lavoie, J.M., et al.
2009. Resistance training does not contribute to improving the metabolic
proﬁle after a 6-month weight loss program in overweight and obese post-
menopausal women. J. Clin. Endocrinol. Metab. 94(9): 3226–3233. doi:10.1210/
jc.2008-2706. PMID:19567540.
Clark, J.E. 2015. Diet, exercise or diet with exercise: comparing the effectiveness of
treatment options for weight-loss and changes in ﬁtness for adults (18–65 years
old) who are overfat, or obese; systematic review and meta-analysis. J. Diabetes
Metab. Disord. 14: 31. doi:10.1186/s40200-015-0154-1. PMID:25973403.
Clement, K., Vaisse, C., Manning, B.S., Basdevant, A., Guy-Grand, B., Ruiz, J., et al.
1995. Genetic variation in the beta 3-adrenergic receptor and an increased
capacity to gain weight in patients with morbid obesity. N. Engl. J. Med.
333(6): 352–354. doi:10.1056/NEJM199508103330605. PMID:7609752.
Corbalan, M.S., Marti, A., Forga, L., Martinez-Gonzalez, M.A., and Martinez, J.A.
2002. The risk of obesity and the Trp64Arg polymorphism of the beta(3)-
adrenergic receptor: effect modiﬁcation by age. Ann. Nutr. Metab. 46(3–4):
152–158. doi:10.1159/000063084. PMID:12169859.
Corella, D., Guillen, M., Portoles, O., Sorli, J.V., Alonso, V., Folch, J., et al. 2001.
Gender speciﬁc associations of the Trp64Arg mutation in the beta3-
adrenergic receptor gene with obesity-related phenotypes in a Mediterranean
population: interaction with a common lipoprotein lipase gene variation.
J. Intern. Med. 250(4): 348–360. doi:10.1046/j.1365-2796.2001.00894.x. PMID:
11576322.
Curioni, C.C., and Lourenco, P.M. 2005. Long-term weight loss after diet and
exercise: a systematic review. Int. J. Obes. (Lond.), 29(10): 1168–1174. doi:10.
1038/sj.ijo.0803015. PMID:15925949.
Dapcich,V., SalvadorCastell, G., RibasBarba, L., PérezRodrigo, C., ArancetaBartrina, J.,
and SerraMajem, L. 2004. Guía de la alimentación saludable. Sociedad Española
de Nutrición Comunitaria, 105 pp. Available from http://aesan.msssi.gob.es/
AESAN/docs/docs/publicaciones_estudios/nutricion/guia_alimentacion.pdf.
Del Corral, P., Chandler-Laney, P.C., Casazza, K., Gower, B.A., and Hunter, G.R.
2009. Effect of dietary adherence with or without exercise on weight loss: a
mechanistic approach to a global problem. J. Clin. Endocrinol. Metab. 94(5):
1602–1607. doi:10.1210/jc.2008-1057. PMID:19258409.
Donnelly, J.E., Blair, S.N., Jakicic, J.M., Manore, M.M., Rankin, J.W., and
Smith, B.K. 2009. American College of Sports Medicine Position Stand. Ap-
propriate physical activity intervention strategies for weight loss and preven-
tion of weight regain for adults. Med. Sci. Sports Exerc. 41(2): 459–471. doi:
10.1249/MSS.0b013e3181949333. PMID:19127177.
Echwald, S.M., Sorensen, T.I., Tybjaerg-Hansen, A., Andersen, T., and
Pedersen, O. 1998. Gln27Glu variant of the human beta2-adrenoreceptor
gene is not associated with early-onset obesity in Danish men. Diabetes,
47(10): 1657–1658. doi:10.2337/diabetes.47.10.1657. PMID:9753308.
Enoksson, S., Talbot, M., Rife, F., Tamborlane,W.V., Sherwin, R.S., and Caprio, S.
2000. Impaired in vivo stimulation of lipolysis in adipose tissue by selective
beta2-adrenergic agonist in obese adolescent girls. Diabetes, 49(12): 2149–
2153. doi:10.2337/diabetes.49.12.2149. PMID:11118019.
Fox, C.S., Liu, Y., White, C.C., Feitosa, M., Smith, A.V., Heard-Costa, N., et al. 2012.
Genome-wide association for abdominal subcutaneous and visceral adipose
reveals a novel locus for visceral fat in women. PLoS Genet. 8(5): e1002695.
doi:10.1371/journal.pgen.1002695. PMID:22589738.
Franz, M.J., VanWormer, J.J., Crain, A.L., Boucher, J.L., Histon, T., Caplan, W.,
et al. 2007. Weight-loss outcomes: a systematic review and meta-analysis of
weight-loss clinical trials with a minimum 1-year follow-up. J. Am. Diet. As-
soc. 107(10): 1755–1767. doi:10.1016/j.jada.2007.07.017. PMID:17904936.
Gagnon, J., Mauriege, P., Roy, S., Sjostrom, D., Chagnon, Y.C., Dionne, F.T., et al.
1996. The Trp64Arg mutation of the beta3 adrenergic receptor gene has no
effect on obesity phenotypes in the Quebec Family Study and Swedish Obese
Subjects cohorts. J. Clin. Invest. 98(9): 2086–2093. doi:10.1172/JCI119014.
PMID:8903328.
Garenc, C., Perusse, L., Rankinen, T., Gagnon, J., Leon, A.S., Skinner, J.S., et al.
2001. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is
not associated with training-induced changes in body composition: The
HERITAGE Family Study. Obes. Res. 9(6): 337–341. doi:10.1038/oby.2001.43.
PMID:11399779.
Garenc, C., Perusse, L., Chagnon, Y.C., Rankinen, T., Gagnon, J., Borecki, I.B.,
et al. 2003. Effects of beta2-adrenergic receptor gene variants on adiposity:
the HERITAGE Family Study. Obes. Res. 11(5): 612–618. doi:10.1038/oby.2003.
88. PMID:12740450.
Gonzalez Sanchez, J.L., Proenza, A.M., Martinez Larrad, M.T., Ramis, J.M.,
Fernandez Perez, C., Palou, A., et al. 2003. The glutamine 27 glutamic acid
polymorphism of the beta2-adrenoceptor gene is associated with abdominal
obesity and greater risk of impaired glucose tolerance in men but not in
women: a population-based study in Spain. Clin. Endocrinol. (Oxf.), 59(4):
476–481. doi:10.1046/j.1365-2265.2003.01871.x. PMID:14510910.
Green, S., Turki, J., Hall, I., and Liggett, S. 1995. Implications of genetic variability
of human 2-adrenergic receptor structure. Pulm. Pharmacol. 8(1): 1–10. doi:
10.1006/pulp.1995.1001. PMID:8535093.
Hagstrom-Toft, E., Enoksson, S., Moberg, E., Bolinder, J., and Arner, P. 1998.
beta-Adrenergic regulation of lipolysis and blood ﬂow in human skeletal
muscle in vivo. Am. J. Physiol. 275(6): E909–E916. PMID:9843731.
Hunter, G.R., Wetzstein, C.J., Fields, D.A., Brown, A., and Bamman, M.M. 2000.
Resistance training increases total energy expenditure and free-living phys-
ical activity in older adults. J. Appl. Physiol. (1985), 89(3): 977–984. PMID:
10956341.
Jalba, M.S., Rhoads, G.G., and Demissie, K. 2008. Association of codon 16 and
codon 27 beta 2-adrenergic receptor gene polymorphisms with obesity: a meta-
analysis. Obesity (Silver Spring), 16(9): 2096–2106. doi:10.1038/oby.2008.327. PMID:
19186333.
Kortner, B., Wolf, A., Wendt, D., Beisiegel, U., and Evans, D. 1999. Lack of
association between a human beta-2 adrenoceptor gene polymorphism
(gln27glu) andmorbid obesity. Int. J. Obes. Relat. Metab. Disord. 23(10): 1099–
1100. doi:10.1038/sj.ijo.0801063. PMID:10557032.
Kurokawa, N., Young, E.H., Oka, Y., Satoh, H., Wareham, N.J., Sandhu, M., et al.
2008. The ADRB3 Trp64Arg variant and BMI: a meta-analysis of 44 833 indi-
viduals. Int. J. Obes. 32(8): 1240–1249. doi:10.1038/ijo.2008.90. PMID:18574485.
Lafontan,M., Barbe, P., Galitzky, J., Tavernier, G., Langin, D., Carpene, C., et al. 1997.
Adrenergic regulation of adipocyte metabolism. Hum. Reprod. 12(Suppl. 1):
6–20. doi:10.1093/humrep/12.suppl_1.6. PMID:9403317.
Lange, L.A., Norris, J.M., Langefeld, C.D., Nicklas, B.J., Wagenknecht, L.E.,
Saad, M.F., et al. 2005. Association of adipose tissue deposition and beta-2
adrenergic receptor variants: the IRAS family study. Int. J. Obes. (Lond.), 29(5):
449–457. doi:10.1038/sj.ijo.0802883. PMID:15672110.
Large, V., Hellstrom, L., Reynisdottir, S., Lonnqvist, F., Eriksson, P., Lannfelt, L.,
et al. 1997. Human beta-2 adrenoceptor gene polymorphisms are highly fre-
quent in obesity and associate with altered adipocyte beta-2 adrenoceptor
function. J. Clin. Invest. 100(12): 3005–3013. doi:10.1172/JCI119854. PMID:
9399946.
Szendrei et al. 313
Published by NRC Research Press
A
pp
l. 
Ph
ys
io
l. 
N
ut
r. 
M
et
ab
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Ba
rb
ar
a 
Sz
en
dr
ei
 o
n 
02
/2
9/
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., et al. 2015.
Genetic studies of body mass index yield new insights for obesity biology.
Nature, 518(7538): 197–206. doi:10.1038/nature14177. PMID:25673413.
Loos, R.J., and Rankinen, T. 2005. Gene-diet interactions on body weight
changes. J. Am. Diet. Assoc. 105(5 Suppl. 1): S29–S34. doi:10.1016/j.jada.2005.
02.015. PMID:15867893.
Macho-Azcarate, T., Marti, A., Gonzalez, A., Martinez, J.A., and Ibanez, J. 2002.
Gln27Glu polymorphism in the beta2 adrenergic receptor gene and lipid
metabolism during exercise in obese women. Int. J. Obes. Relat. Metab. Dis-
ord. 26(11): 1434–1441. doi:10.1038/sj.ijo.0802129. PMID:12439644.
Marti, A., Corbalan, M.S., Martinez-Gonzalez, M.A., and Martinez, J.A. 2002.
TRP64ARG polymorphism of the beta 3-adrenergic receptor gene and obesity
risk: effect modiﬁcation by a sedentary lifestyle. Diabetes Obes. Metab. 4(6):
428–430. doi:10.1046/j.1463-1326.2002.00227.x. PMID:12406043.
Martinez, J.A., Corbalan, M.S., Sanchez-Villegas, A., Forga, L., Marti, A., and
Martinez-Gonzalez, M.A. 2003. Obesity risk is associated with carbohydrate
intake in women carrying the Gln27Glu beta2-adrenoceptor polymorphism.
J. Nutr. 133(8): 2549–2554. PMID:12888635.
Meirhaeghe, A., Helbecque, N., Cottel, D., and Amouyel, P. 1999. Beta2-
adrenoceptor gene polymorphism, body weight, and physical activity. Lan-
cet, 353(9156): 896. doi:10.1016/S0140-6736(99)00251-2. PMID:10093985.
Meirhaeghe, A., Helbecque, N., Cottel, D., and Amouyel, P. 2000. Impact of
polymorphisms of the human beta2-adrenoceptor gene on obesity in a
French population. Int. J. Obes. Relat. Metab. Disord. 24(3): 382–387. doi:10.
1038/sj.ijo.0801168. PMID:10757635.
Monroe, M.B., Seals, D.R., Shapiro, L.F., Bell, C., Johnson, D., and Parker Jones, P.
2001. Direct evidence for tonic sympathetic support of restingmetabolic rate
in healthy adult humans. Am. J. Physiol. Endocrinol. Metab. 280(5): E740–
E744. PMID:11287356.
Murphy, S.L. 2009. Review of physical activity measurement using accelerome-
ters in older adults: considerations for research design and conduct. Prev.
Med. 48(2): 108–114. doi:10.1016/j.ypmed.2008.12.001. PMID:19111780.
National Institutes of Health. 1998. Clinical Guidelines on the Identiﬁcation,
Evaluation, and Treatment of Overweight and Obesity in Adults–The Evi-
dence Report. National Institutes of Health. Obes. Res. 6(Suppl. 2): 51S–209S.
PMID:9813653.
Ordovas, J.M., and Shen, J. 2008. Gene-environment interactions and suscepti-
bility to metabolic syndrome and other chronic diseases. J. Periodontol. 79(8
Suppl.): 1508–1513. doi:10.1902/jop.2008.080232. PMID:18673004.
Pereira, A.C., Floriano, M.S., Mota, G.F., Cunha, R.S., Herkenhoff, F.L., Mill, J.G.,
et al. 2003. Beta2 adrenoceptor functional gene variants, obesity, and blood
pressure level interactions in the general population. Hypertension, 42(4):
685–692. doi:10.1161/01.HYP.0000085648.65419.17. PMID:12900437.
Phares, D.A., Halverstadt, A.A., Shuldiner, A.R., Ferrell, R.E., Douglass, L.W.,
Ryan, A.S., et al. 2004. Association between body fat response to exercise
training andmultilocusADRgenotypes. Obes. Res. 12(5): 807–815. doi:10.1038/
oby.2004.97. PMID:15166301.
Rauhio, A., Uusi-Rasi, K., Nikkari, S.T., Kannus, P., Sievanen, H., and Kunnas, T.
2013. Association of the FTO and ADRB2 genes with body composition and fat
distribution in obese women. Maturitas, 76(2): 165–171. doi:10.1016/j.maturitas.
2013.07.004. PMID:23911093.
Rawson, E.S., Nolan, A., Silver, K., Shuldiner, A.R., and Poehlman, E.T. 2002. No
effect of the Trp64Arg beta(3)-adrenoceptor gene variant onweight loss, body
composition, or energy expenditure in obese, caucasian postmenopausal
women. Metabolism, 51(6): 801–805. doi:10.1053/meta.2002.32781. PMID:
12037740.
Rosado, E.L., Bressan, J., and Martinez, J.A. 2015. Environmental factors and
beta2-adrenergic receptor polymorphism: inﬂuence on the energy expendi-
ture and nutritional status of obese women. Lipids, 50(5): 459–467. doi:10.
1007/s11745-015-4012-1. PMID:25893811.
Ruiz, J.R., Larrarte, E., Margareto, J., Ares, R., and Labayen, I. 2011. Role of beta(2)-
adrenergic receptor polymorphisms on body weight and body composition
response to energy restriction in obese women: preliminary results. Obesity
(Silver Spring), 19(1): 212–215. doi:10.1038/oby.2010.130. PMID:20523301.
Rutter, M.K., Massaro, J.M., Hoffmann, U., O’Donnell, C.J., and Fox, C.S. 2012.
Fasting glucose, obesity, and coronary artery calciﬁcation in community-
based people without diabetes. Diabetes Care, 35(9): 1944–1950. doi:10.2337/
dc11-1950. PMID:22773705.
Shungin, D., Winkler, T.W., Croteau-Chonka, D.C., Ferreira, T., Locke, A.E.,
Magi, R., et al. 2015. New genetic loci link adipose and insulin biology to body
fat distribution. Nature, 518(7538): 187–196. doi:10.1038/nature14132. PMID:
25673412.
Speliotes, E.K., Willer, C.J., Berndt, S.I., Monda, K.L., Thorleifsson, G.,
Jackson, A.U., et al. 2010. Association analyses of 249,796 individuals reveal 18
new loci associated with body mass index. Nat. Genet. 42(11): 937–948. doi:
10.1038/ng.686. PMID:20935630.
Tchernof, A., Starling, R.D., Turner, A., Shuldiner, A.R., Walston, J.D., Silver, K.,
et al. 2000. Impaired capacity to lose visceral adipose tissue during weight
reduction in obese postmenopausal women with the Trp64Arg beta3-
adrenoceptor gene variant. Diabetes, 49(10): 1709–1713. doi:10.2337/diabetes.
49.10.1709. PMID:11016455.
Ukkola, O., Rankinen, T., Rice, T., Gagnon, J., Leon, A.S., Skinner, J.S., et al. 2003.
Interactions among the beta2- and beta3- adrenergic receptor genes and total
body fat and abdominal fat level in the HERITAGE Family Study. Int. J.
Obes. Relat. Metab. Disord. 27(3): 389–393. doi:10.1038/sj.ijo.0802248.
PMID:12629568.
Ukkola, O., Rankinen, T.,Weisnagel, S.J., Sun, G., Perusse, L., Chagnon, Y.C., et al.
2000. Interactions among the alpha2-, beta2-, and beta3-adrenergic receptor
genes and obesity-related phenotypes in the Quebec Family Study. Metabo-
lism, 49(8): 1063–1070. doi:10.1053/meta.2000.7708. PMID:10954027.
Widen, E., Lehto, M., Kanninen, T., Walston, J., Shuldiner, A.R., and Groop, L.C.
1995. Association of a polymorphism in the 3-adrenergic–receptor gene
with features of the insulin resistance syndrome in Finns. N. Engl. J. Med.
333(6): 348–352. doi:10.1056/NEJM199508103330604. PMID:7609751.
Zapico, A.G., Benito, P.J., Gonzalez-Gross, M., Peinado, A.B., Morencos, E.,
Romero, B., et al. 2012. Nutrition and physical activity programs for obesity
treatment (PRONAF study): methodological approach of the project. BMC
Public Health, 12(1): 1100. doi:10.1186/1471-2458-12-1100. PMID:23259716.
314 Appl. Physiol. Nutr. Metab. Vol. 41, 2016
Published by NRC Research Press
A
pp
l. 
Ph
ys
io
l. 
N
ut
r. 
M
et
ab
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Ba
rb
ar
a 
Sz
en
dr
ei
 o
n 
02
/2
9/
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
